2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 291-292
Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Gene Editing, Treatment Considerations, Non-Biological Therapies, Pharmacology, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Embryo/Fetus, Animal Model
PAPER

485 Progenitor-directed GLP-1 receptor agonism restrains clonal hematopoiesis: Convergent human clinical and transcriptomic evidence

Mark David Orland, MD, PhD, Dongxu Jiang, PhD2, Nandini Rajaram Siva, MD3, Yahan Zhang, MS4, Atsushi Marumo, MD5, Zachary Brady, BS6, Arda Durmaz, PhD7, Aashray Mandala, BS8, Serhan Unlu, MD9, Kartik Lakhotiya, MS10, Carmelo Gurnari, MD,PhD11, Babal Kant Jha, PhD12, Valeria Visconte, PhD13, Jaroslaw P. Maciejewski, MD, PhD, FACP14
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Cleveland Clinic, Cleveland, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States

Clonal hematopoiesis (CH), clonal cytopenia of undetermined significance (CCUS), and myelodysplastic syndrome (MDS) form a biological continuum and are major drivers of hematologic malignancy and cardiovascular disease, yet no therapy intercepts clonal expansion before malignant transformation. This investigation originated from an unexpected clinical observation of clonal contraction following glucagon-like peptide-1 receptor agonists (GLP-1RA) initiation. We interrogated publicly available transcriptomic datasets spanning normal hematopoiesis and myeloid diseases, evaluated 10 patients on GLP-1RA undergoing serial molecular monitoring and a prospective STAY-LEAN trial, a registry evaluating patients with obesity for the effects of GLP-1RA on weight and CH, and modeled clonal fitness in vivo using competitive Tet2+/- bone marrow transplants, randomizing engrafted recipients to semaglutide (100 nmol/kg subcutaneously weekly) or vehicle for 20 weeks with mutant chimerism tracked by flow cytometry. Because GLP-1RA, beyond their metabolic effects, suppress inflammatory signaling and improve immune homeostasis, we hypothesized that GLP-1R agonism reduces the selective pressures favoring mutant hematopoietic stem cells and thereby restrains clonal evolution.

Hematopoietic hierarchy analysis demonstrated that GLP1R expression was highest within hematopoietic stem cells and progressively declined across committed progenitors and mature myeloid populations, positioning GLP-1R signaling at the earliest stages of clonal selection. Higher GLP1R expression was associated with reduced inflammatory signaling, including suppression of TNF-alpha/NF-kB, IL6/JAK/STAT3, IFN-g and inflammatory response pathways, and reduced proliferative programs (MYC, E2F, G2M, mTORC1). Weighted gene co-expression network analysis identified GLP1R-associated hubs enriched for inflammatory and cell-cycle regulation, with inverse relationships between GLP1R and STAT3, NF-kB1, and JAK2; these findings were independently replicated in an external cohort (TCGA-AML; n=173).

We next examined clonal dynamics in patients (3 CHIP, 4 low-risk MDS, and 3 paroxysmal nocturnal hemoglobinuria [PNH]) receiving GLP-1RA for standard indications; none received hypomethylating agents or lenalidomide, and serial sequencing spanned epigenetic regulators, spliceosome genes, signaling pathways, and PIGA. Every patient demonstrated stabilization or reduction of clonal burden with no progressive expansion, and relative reductions approached 60%. Representative examples included an SF3B1-mutant MDS patient whose variant allele fraction declined from 38% to 14% with concurrent transfusion independence, and a TET2-mutant clone that became undetectable on serial sequencing. All three PNH patients demonstrated contraction of GPI-deficient granulocyte clones despite unchanged complement inhibitor therapy, supporting reduced mutant stem-cell fitness rather than altered terminal complement control. In STAY-LEAN (n=15), CHIP clone burden declined over nine months of GLP-1RA, supporting restraint before overt neoplasia. In the competitive Tet2+/- model, the mutant (tdTomato+) clone expanded aggressively in all arms, rising from approximately 25% to 74% chimerism by week 20, with no significant difference between GLP-1RA and placebo (n=10 [5 male, 5 female] per group; preliminary, studies and analyses ongoing), consistent with an indirect, milieu-directed mechanism rather than direct clone elimination. Immunophenotypic and inflammatory profiling are ongoing and, though not the primary focus, will further test this mechanism.

In sum, transcriptomic analyses, prospective molecular monitoring, and preliminary murine studies are consistent with a model in which GLP-1R agonism acts at the level of hematopoietic stem and progenitor cells to restrain clonal evolution rather than directly eliminate established mutant clones. These findings identify progenitor-directed GLP-1R agonism as a potential disease-interception strategy across the CHIP-MDS continuum and provide a biological rationale for prospective clinical trials evaluating GLP-1R agonists to prevent clonal progression and myeloid malignancy.

Mark David Orland, MD, PhD: No relevant conflicts of interest to declare.